Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Pfizer

Status and phase: Completed; Phase 3

Conditions: Invasive Pneumococcal Disease (IPD); Neisseria Meningitidis (Bacterial Meningitis)

Treatments: Biological: 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7); Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7); Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00617760

670701

Details and patient eligibility

About

The purpose of this study in healthy toddlers who have not previously been immunized against MenC infection and who completed their primary immunization series with PCV-7 (3 vaccinations) during infancy is to demonstrate that the concomitant administration of a single dose of MenC-TT vaccine and a PCV7 booster does not influence the immune response to the seven pneumococcal strains contained in PCV7 as compared to administration of PCV7 alone, and does not influence the immune response to the MenC-TT vaccine as compared to administration of MenC-TT vaccine alone.

Enrollment: 330 patients

Sex: All

Ages: 12 to 18 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Male and female subjects will be eligible for participation in this study if:

• they are toddlers, aged 12 to 18 months
• they are clinically healthy (i.e. the physician would have no reservations vaccinating with a MenC conjugate vaccine, and/or PCV7 outside the scope of a clinical trial)
• their parents/legal guardian(s) understand the nature of the study, agree to its provisions, and provide written informed consent
• their parents/legal guardian(s) agree to keep a Subject Diary
• they have received a complete primary series of pneumococcal conjugate vaccine (3 vaccinations with PCV7 in the first year of life according to the official vaccination calendar recommendations)

Exclusion criteria

Subjects will be excluded from participation in this study if:

• they have a history of any vaccine-related contraindicating event, e.g. serious reactions after first application of a PCV7 vaccine or high fever >= 40ºC associated with any vaccination, or generalized allergic reaction within 48 hours of a first application of vaccine
• they have a known sensitivity or allergy to any components of the vaccines
• they have previously been vaccinated with MenC vaccine
• they have already received a PCV 7 booster (4th vaccination)
• they have a rash or other dermatological condition at the injection site which could interfere with injection site reaction evaluation
• they suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions
• they have a history of meningococcal serogroup C and/or invasive pneumococcal infection
• they have received any blood products or immunoglobulins within 90 days of study entry or the administration of such products is planned during the study period
• currently have or had a history of any serious disease (e.g. cardiac, renal, autoimmune, neurologic)
• were administered an investigational drug within 6 weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product
• they or their parents /legal guardian(s) are in a dependent relationships with the study investigator or with a study team member. Dependent relationships include close relatives (i.e., children or grandchildren, partner/spouse, siblings) as well as employees of the investigator or site conducting the study.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

330 participants in 3 patient groups

1

Experimental group

Description:

Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects

Treatment:

Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)

2

Active Comparator group

Description:

PCV7 administration only, 85 subjects

Treatment:

Biological: 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)

3

Active Comparator group

Description:

MenC-TT vaccine only, 85 subjects

Treatment:

Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)